Wine-based antioxidant could shield against radiation exposure
An antioxidant contained in red table wine could one day prove effective as protection against radiation from a nuclear attack, according to a study by University of Pittsburgh researchers.
An antioxidant contained in red table wine could one day prove effective as protection against radiation from a nuclear attack, according to a study by University of Pittsburgh researchers.
The University of Pittsburgh's Center for Medical Countermeasures Against Radiation is dedicated to discovering and developing drugs that can be used as quick "antidotes" to mitigate or protect against the effects of radiation exposure in case of a large-scale radiological or nuclear emergency.
These new, small molecules with radioprotective capacity will be required for treatment in case of radiation spills or even as countermeasures against radiological terrorism, said lead investigator Dr. Joel Greenberger, chair of radiation oncology at Pitt's School of Medicine.
Greenberg and colleagues have been investigating the protective properties of resveratrol, a natural antioxidant commonly found in red wine and many plants. The investigators found that resveratrol, when altered with acetyl, proved to shield mouse cells to the effects of radiation. Their results were presented Sept. 23 at the 2008 American Society for Therapeutic Radiology and Oncology meeting in Boston.
"Small molecules that can be easily stored, transported, and administered are optimal for this, and so far acetylated resveratrol fits these requirements well," Greenberger said.
Greenberger's team is conducting further studies to determine if acetylated resveratrol can be used clinically as a radioprotective agent. His group had already made news in 2004 when they discovered the agent JP4-039, which can be delivered directly to mitochondria to resist radiation-induced cell death.
"Currently, there are no drugs on the market that protect against or counteract radiation exposure," Greenberg said. "Our goal is to develop treatments for the general population that are effective and nontoxic."
For more information from the Diagnostic Imaging archives:
Holiday travel can ring more than jingle bells
Dirty bombs: More fear than substance
ACR primer helps prepare for radiological terrorism
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
AMA Approves Category III CPT Codes for AI-Enabled Perivascular Fat Analysis from CT Scans
April 9th 2025Going into effect in 2026, the new CPT codes may facilitate increased adoption of the CaRi-Heart software for detecting coronary inflammation from computed tomography scans pending FDA clearance of the technology.
FDA Clears AI Assessment of Ischemic Core Volume on CT with Brainomix 360 Platform
April 8th 2025For patients with acute ischemic stroke, research has demonstrated that automated assessment of ischemic core volume on brain CT scans via the Brainomix 360 software is equivalent to that derived from CT perfusion.
